Home
Storia in 1 fonti
Brand-name drug prices climb after launch in US, fall abroad amid MFN push: report
In the U.S., many top brand-name drugs continue to get more expensive with age, while the same medicines often get cheaper in peer countries, according to an AARP Public Policy Institute
Raccontata da
fiercepharma.com
Timeline cronologica
- ·
Cancer is changing. Is pharma marketing changing with it?
Early-onset cancers are rising among adults 18–49, reshaping how patients are diagnosed, supported, and engaged. This report examines key trends, gaps in care, and how data and…
- ·
Pharma leaders meet with PM Takaichi in push for Japan to retain R&D edge
With China's growing dominance in the biopharma R&D sector, a collection of g | A group of over 20 global pharma leaders met with Japan's Prime Minister Sanae Takaichi to address…
- ·
Pharma urged to modernize patient support as young adult cancer rates rise
Pharma companies need to strengthen and modernize patient support programs to reflect rising rates of cancer in adults aged 18 to 49 years, an Omnicom Health report found. |…
- ·
Brand-name drug prices climb after launch in US, fall abroad amid MFN push: report
In the U.S., many top brand-name drugs continue to get more expensive with age, while the same medicines often get cheaper in peer countries, according to an AARP Public Policy…
- ·
Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed assets gain more attention from biopharma…